Abstract:Background/Aims: Accumulating evidence revealed that microRNAs (miRNAs) have been demonstrated as critical molecules in tumor development and progression. MiR-26a, located in a fragile chromosomal region associated with various human cancer, has been reported to be involved in regulating various cellular process, such as proliferation, apoptosis and invasion through targeting multiple oncogene. Docetaxel-mediated chemotherapy has been applied in improving the survival and prognosis of patients with advanced lung adenocarcinoma (LAD). However, chemoresistance remains a major impediment to clinical application of this agent. It has been presented that decreased miR-26a expression lead to cisplatin resistance and promoted growth and migration in human lung cancer. Enhancer of zeste homolog 2 (EZH2) is the target of miR-26a. The present study aimed to investigate the function of miR-26a/EZH2 in the acquisition of malignant behaviors of LAD. Methods: MiR-26a and EZH2 expression levels in the dcetaxel-insensitive groups (n = 19) and the docetaxel-sensitive groups (n = 18) were assessed by qRT-PCR. Colony formation assay, flow cytometric analysis, wound healing assay, cell transwell assays and western blotting were performed to assess the effects of miR-26a on proliferation, apoptosis and epithelial-to-mesenchymal (EMT) phenotypes in docetaxel resistant LAD cells in vitro. Xenograft transplantation, immunohistochemistry, tunel assays and western blotting assays were employed to demonstrate the role of miR-26a in docetaxel resistant LAD cells in vivo. The expression level of EZH2 in docetaxel-resistant LAD cells and corresponding parental cells was detected by qRT-PCR and western blotting. The relationship between miR-26a and EZH2 was confirmed by luciferase reporter assay. And rescue assays were performed to further confirm that miRNA-26a contributes to the acquisition of malignant behaviors of docetaxel-resistant LAD cells through targeting EZH2. Results: MiR-26a was significantly down-regulated in the dcetaxel-insensitive groups (n = 19) compared with the docetaxel-sensitive groups (n = 18) assessed by qRT-PCR. MiR-26a decreased the proliferation, increased the apoptosis rate and reversed EMT to MET of docetaxel-resistant LAD cells both in vivo and vitro. EZH2 was confirmed as target of miR-26a. Rescue assays further verified that the function of miR-26a exerts in docetaxel-resistant LAD cells is through targeting EZH2. Conclusions: Our data revealed that overexpression of miR-26a in docetaxel-resistant LAD cells could decrease the proliferation, increase the apoptosis rate and reverse EMT to MET of docetaxel-resistant LAD cells both in vivo and vitro and such function is partially exerted via downregulating EZH2. MiR-26a/EZH2 signal pathway makes contribute to the malignant phenotype of docetaxel-resistant of LAD cells which indicated that miR-26a exerts pivotal functions in the molecular etiology of chemoresistant lung adenocarcinoma.

Acquisition of Radioresistance in Docetaxel-Resistant Human Lung Adenocarcinoma Cells is Linked with Dysregulation of Mir-451/C-myc-survivin/rad-51 Signaling

Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling.

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

MicroRNA-451 Induces Epithelial–mesenchymal Transition in Docetaxel-Resistant Lung Adenocarcinoma Cells by Targeting Proto-Oncogene C-Myc

Mirna‑885‑3p Inhibits Docetaxel Chemoresistance in Lung Adenocarcinoma by Downregulating Aurora A.

Hdac 1/4-Mediated Silencing of Microrna-200b Promotes Chemoresistance in Human Lung Adenocarcinoma Cells

MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells Through Targeting EZH2

Identification of Microrna Profiles in Docetaxel-Resistant Human Non-Small Cell Lung Carcinoma Cells (SPC-A1)

MicroRNA-650 Was a Prognostic Factor in Human Lung Adenocarcinoma and Confers the Docetaxel Chemoresistance of Lung Adenocarcinoma Cells Via Regulating Bcl-2/Bax Expression

MiR-140-3p Improves Sensitivity to Docetaxel by Suppressing PD-L1/ABCG2/MVP Expression in Lung Adenocarcinoma

Long Noncoding Rna Ror Regulates Chemoresistance In Docetaxel-Resistant Lung Adenocarcinoma Cells Via Epithelial Mesenchymal Transition Pathway

MiR-100 Resensitizes Docetaxel-Resistant Human Lung Adenocarcinoma Cells (SPC-A1) to Docetaxel by Targeting Plk1

Let-7c Governs the Acquisition of Chemo- or Radioresistance and Epithelial-to-mesenchymal Transition Phenotypes in Docetaxel-Resistant Lung Adenocarcinoma.

miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

MARCKSL1–2 Reverses Docetaxel-Resistance of Lung Adenocarcinoma Cells by Recruiting SUZ12 to Suppress HDAC1 and Elevate Mir-200B

Notch-1 Confers Chemoresistance in Lung Adenocarcinoma to Taxanes Through AP-1/microRNA-451 Mediated Regulation of MDR-1

MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.

A Double-Negative Feedback Loop Between E2F3b and Mir- 200b Regulates Docetaxel Chemosensitivity of Human Lung Adenocarcinoma Cells.

Histone Deacetylase 1/Sp1/microrna-200B Signaling Accounts for Maintenance of Cancer Stem-Like Cells in Human Lung Adenocarcinoma

Microrna-137 Inhibits Tumor Growth And Sensitizes Chemosensitivity To Paclitaxel And Cisplatin In Lung Cancer

miR-140-3p enhances cisplatin sensitivity and attenuates stem cell-like properties through repressing Wnt/β-catenin signaling in lung adenocarcinoma cells